BioAdaptives, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 09:22 pm
Share
BioAdaptives, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.003337 million compared to USD 0.005342 million a year ago. Net loss was USD 0.276325 million compared to USD 0.034516 million a year ago.
For the nine months, sales was USD 0.013192 million compared to USD 0.015925 million a year ago. Net loss was USD 0.867293 million compared to USD 0.835665 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.
BioAdaptives, Inc. manufactures and distributes natural plant and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. Its product line for humans includes PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore. It also markets the Lung Flute and PrimiLungs products in its Lung Armor packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the device. Its animal products include an Equine All-in-One and Equine All-In-One Plus formulation, which it markets to trainers, horse owners and boarding stables, and a Canine All-in-One.